![]() ![]() The analysis technique used in this trial was based on the foundational work by Evans and Follman, where the study patient’s experiences are compared between the two treatment groups, allowing multiple outcomes to be counted for a given patient. Clinical trials traditionally have a separate comparison between the study groups for each study outcome. Like many treatment decisions, determining the optimal thromboprophylaxis regimen for a given patient requires clinicians to weigh the benefits and risks of the available treatment options. ![]() Based on the lack of scientific support for various regimens in this population, the Orthopaedic Trauma Association Evidence-Based Quality Value and Safety Committee recently emphasized the need for standardized VTE prevention guidelines to improve care. Considering that orthopaedic trauma patients often have multiple injuries that may increase VTE and bleeding risks, drawing inference from the arthroplasty literature is cautioned. To date, most randomized studies comparing these regimens have been conducted in the arthroplasty population. As a result, the ACCP guidelines now include aspirin as an option for high-risk orthopaedic surgery patients. However, many orthopaedic trauma surgeons prefer aspirin in light of recent studies suggesting aspirin may be an effective alternative in VTE prevention with a reduced likelihood of bleeding and wound complications. ![]() The Eastern Association for the Surgery of Trauma and the American College of Chest Physicians (ACCP) recommend low-molecular-weight heparin (LMWH) for VTE prophylaxis in trauma patients. Trauma is a well-described risk factor for venous thromboembolism (VTE), but controversy exists regarding the optimal thromboprophylaxis regimen following orthopaedic trauma. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ĭata Availability: All relevant data are within the manuscript and its Supporting Information files.įunding: The study was not funded, nor did any of the authors receive salary support from a funder for the research described in the manuscript.Ĭompeting interests: The authors have declared that no competing interests exist. Received: FebruAccepted: JPublished: August 3, 2020Ĭopyright: © 2020 Haac et al. PLoS ONE 15(8):Įditor: Christophe Leroyer, Universite de Bretagne Occidentale, FRANCE (2020) Aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in orthopaedic trauma patients: A patient-centered randomized controlled trial. Citation: Haac BE, O'Hara NN, Manson TT, Slobogean GP, Castillo RC, O'Toole RV, et al. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |